FMP
Palisade Bio, Inc.
PALI
NASDAQ
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal tract. Its lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor that is intended to inhibit digestive enzyme activity and preserve gut integrity during intestinal stress resulting from reduced blood flow to the intestine, infections, or due to surgery. The company was founded in 2005 and is headquartered in Carlsbad, California.
4.26 USD
0.085 (1.99%)
About
ceo
Mr. J. D. Finley
sector
Healthcare
industry
Biotechnology
website
https://www.palisadebio.comexchange
NASDAQ
Description
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal tract. Its lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor that is intended to inhibit digestive enzyme activity and preserve gut integrity during intestinal stress resulting from reduced blood flow to the intestine, infections, or due to surgery. The company was founded in 2005 and is headquartered in Carlsbad, California.
CIK
0001357459
ISIN
US6963892046
CUSIP
696389105
Address
5800 Armada Drive
Phone
858 704 4900
Country
US
Employee
9
IPO Date
Mar 30, 2007
Summary
CIK
0001357459
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
696389105
ISIN
US6963892046
Country
US
Price
4.26
Beta
1.3
Volume Avg.
259.64k
Market Cap
3.99M
Shares
-
52-Week
3.82-34.35
DCF
13.61
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-0.18
P/B
-
Website
https://www.palisadebio.com
Historical Prices
We are unable to load the chart at this time.
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
Upgrades and Downgrades
We are unable to load this data!
People Also Watch
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest PALI News
It looks like there's no news available.
